AUTHORS
Yongxia Wu, MD, PhD, Allison Pugel2, Xiaohong Yuan, MD3, Reza Alimohammadi, PhD4, Denggang Fu Sr, DF5, Kaipo Yang, MD, PhD6, Victor Jin7, Chien-Wei Lin, PhD8, Xue-Zhong Yu Sr, MD, MSc9
AFFILIATIONS
1 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
5 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
6 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
7 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
8 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
9 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
ABSTRACT
Malignant relapse and graft-versus-host disease (GVHD) remain major barriers to successful allogeneic hematopoietic cell transplantation (allo-HCT). Tissue-resident memory T cells (TRM) sustain local T-cell persistence and GVHD pathogenesis, whereas circulating memory/effector T cells support graft-versus-leukemia (GVL) effect. However, the molecular mechanisms that regulate pathogenic tissue residency versus circulating effector programs remain poorly defined.
To identify regulators of T-cell tissue residency in GVHD, we did scRNA-seq analysis of donor T cells from recipient liver in a haploidentical murine HCT model. We identified two TRM clusters enriched for Cd69, Itga1 and Zfp683, including progenitor TRM and early differentiated TRM, as well as a circulating memory (TCM) cluster enriched for Klf2, S1pr1, and Sell. SCENIC analysis revealed transcription factor networks enriched in progenitor TRM (Fos, Runx1), early TRM (Fli1, Runx3) and TCM (Klf2, Klf3). Given our prior finding that Fli-1 contributes to GVHD pathogenesis and reports that Fli-1 restricts CD8+ effector T cell program, we investigated whether targeting Fli-1 could modulate T-cell residency and effector programs to separate GVHD from GVL activity.
Using a newly validated T-cell-specific Fli1 knockout (KO) model, we found that Fli1 deficiency in donor T cells significantly attenuated GVHD while preserving robust GVL activity. Recipients of Fli1-KO T cells had reduced liver and colon pathology. Spatial transcriptomics of recipient colon showed that Fli1 loss reduced cytotoxic T-cell signatures while increasing protective epithelial barrier markers and short-chain fatty acid metabolic pathways. These data suggest improved colon integrity and metabolic health in the recipient of Fli1-KO T cells. Mechanistically, Fli1 loss significantly reduced TRM cells in recipient liver and colon. Fli1 deficiency broadly impaired CD4+ T-cell expansion. In CD8+ T cells, Fli1 loss reduced expansion in the colon but increased expansion in blood-rich sites, including circulation, spleen, and liver, and enhanced IFNγ production. Intravascular labeling further showed fewer parenchymal resident T cells in the liver of KO T-cell recipients, consistent with reduced liver pathology.
To further determine molecular mechanisms by which Fli-1 regulates T-cell responses in vivo, we isolated donor T cells from recipient liver and performed scRNA-seq analysis. Fli1 deficiency reduced TRM populations while increasing TCM CD8+ T-cell states. Regulon and differential gene expression analyses showed that Fli1 deficiency increased Klf2-driven egress/circulation and effector programs, while reducing Tcf7-associated progenitor maintenance and tissue-residency genes. In CD4+ T cells, Fli1 deficiency also reduced TRM while increasing TCM and Treg populations. Flow cytometry confirmed reduced Ly108+TCF1+ progenitor cells and increased KLRG1+CX3CR1+ circulating/effector-like cells in GVHD tissues and elevated CD44+CD62L+ central-memory-like cells in circulation. Together, these data indicate that Fli-1 supports memory progenitor and tissue-residency programs while limiting circulation-associated effector states.
To validate the role of FLI-1 in human T-cell responses, we targeted FLI1 via CRISPR/Cas9 and found that FLI1 deficiency attenuated CD4+ T-cell expansion while increasing CD8+ T-cell IFNγ production after allogeneic stimulation. During xenogeneic GVHD, human T cells markedly upregulated FLI-1 protein, and FLI1 deficiency reduced human T-cell pathogenicity. To assess clinical relevance, we analyzed published scRNA-seq data on human intestinal GVHD. T cells in GVHD samples exhibited a shift from CXCR6lo toward CXCR6hi TRM subsets and expansion of effector-like T cells. FLI1 expression was enriched in TSCM and CXCR6hi TRM cells and was upregulated in TSCM and TRM populations from GVHD samples compared with controls.
Taken together, we identify Fli-1 as a transcriptional regulator that promotes pathogenic T-cell residency while restraining circulating memory and effector programs. Targeting Fli-1 may provide a novel strategy to attenuate GVHD while preserving GVL activity after allo-HCT.
DISCLOSURES
Yongxia Wu, MD, PhD: No relevant conflicts of interest to declare.